Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,850.00
Bid: 11,700.00
Ask: 12,000.00
Change: 200.00 (1.72%)
Spread: 300.00 (2.564%)
Open: 11,900.00
High: 12,000.00
Low: 11,800.00
Prev. Close: 11,650.00
JDG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update and Notice of Results

25 Jul 2022 07:00

RNS Number : 5214T
Judges Scientific PLC
25 July 2022
 

Judges Scientific Plc

("Judges Scientific", "the Company" or "the Group")

Half Year Trading Update and Notice of Interim Results

Judges Scientific (AIM: JDG), the group focused on acquiring and developing companies in the scientific instrument sector, provides the following update regarding the Group's trading performance for the six-month period ended 30 June 2022.

The period has been one of continued resilience and progress as our Group recovers from the challenges of the pandemic, with much improved travel across most of the Group's markets, whilst still having to navigate worsening supply chain disruptions.

On 23 May 2022, the Group acquired Geotek Holding Limited and Geotek Coring Limited ('Geotek') for a consideration of up to £80m, funded by a new £100m multi-bank facility, which provides the Group with additional capacity to support the Group's buy and build strategy.

References to "Organic" information in this update exclude any contribution from Geotek.

Order intake 

Across the Group, Organic order intake was up 4.2% after a 25.1% gain in H1 2021; this shows 7.8% progress compared to H1 2019 although cannot be considered a full recovery to the pre-Covid growth trajectory. The Group saw growth in North America, up 15.4% (after 41% growth in H1 2021) and the Rest of the World, up 13.1% (after 8% improvement in H1 2021). The Rest of Europe was flat (after 34% growth in H1 last year) reflecting varied performances across the region. China/Hong Kong, which continued to be affected by strict lockdowns over the period, receded 5.1% (after 2% growth in H1 2021). The UK, which had progressed 26% in H1 2021, was down 9.4%. Order intake still varied considerably from business to business, although less so than in H1 2021.

Order book

The Organic order book reached a mid-year record of 21.3 weeks (17.6 weeks at 30 June 2021 and 23 weeks at 1 January 2022), aided by the modest increase in order intake and by the ongoing supply chain difficulties.

Revenue

Organic sales in the first half were up 7% compared with H1 2021. Further progress was hindered by supply chain issues, by staff shortages caused both by recruitment difficulties and by numerous colleagues having to isolate.

First Half Performance and Outlook

The board expects the growth in Organic revenues to have driven improved profitability in H1. Whilst general market conditions remain challenging, our resilient business model, backed up by a strong order book, gives the board confidence that the current market expectations for the full year (revised to include Geotek) will be met. 

 

Notice of Results

The Company intends to announce its interim results for the six months to 30 June 2022 on Thursday 22 September 2022.

 

For further information please contact:

Judges Scientific

David Cicurel, CEO

Brad Ormsby, Group FD

Tel: +44 (0) 20 3829 6970

 

Shore Capital (Nominated Adviser & Broker)

Stephane Auton

Iain Sexton

Tel: +44 (0) 20 7408 4090

 

Liberum (Joint Broker)

Edward Mansfield

William Hall

 

Media enquiries:

Alma PR (Financial Public Relations)

 

Tel: +44 (0) 20 3100 2222

 

Sam Modlin

Justine James

Joe Pederzolli

 

Tel: +44 (0) 20 3405 0205

judges@almapr.co.uk

Notes to editors:

Judges Scientific plc (AIM: JDG), is a group focused on acquiring and developing companies in the scientific instrument sector. The Group now consists of 20 businesses acquired since 2005.

The acquired companies are primarily UK-based with products sold worldwide to a diverse range of markets including: higher education institutions, scientific research facilities, manufacturers and regulatory authorities. The UK is a recognised centre of excellence for scientific instruments. The Group has received five Queen's Awards for innovation and export. 

The Group's companies predominantly operate in global niche markets, with long term growth fundamentals and resilient margins.

Judges Scientific maintains a policy of selectively acquiring businesses that generate sustainable profits and cash. Shareholder returns are created through the reduction of debt, organic growth and dividends. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGZGZNZZFGZZZ
Date   Source Headline
1st Dec 20157:00 amRNSTotal Voting Rights
16th Nov 201510:58 amRNSBlocklisting Interim Review
6th Nov 20154:57 pmRNSDirector/PDMR Shareholding
2nd Nov 20157:00 amRNSTotal Voting Rights
21st Oct 201512:00 pmRNSNew option schemes, Director/PDMR Shareholding
16th Oct 20153:24 pmRNSDirector/PDMR Shareholding
8th Oct 20155:08 pmRNSDirector/PDMR Shareholding
7th Oct 20152:10 pmRNSDirector/PDMR Shareholding
1st Oct 20157:00 amRNSTotal Voting Rights
28th Sep 20156:00 pmRNSDirector/PDMR Shareholding
25th Sep 20157:00 amRNSHalf Yearly Report
14th Sep 20155:29 pmRNSDirector/PDMR Shareholding
1st Sep 20157:03 amRNSTotal Voting Rights
7th Aug 20157:00 amRNSDirector/PDMR Shareholding
24th Jul 20155:21 pmRNSDirector/PDMR Shareholding and Notice of Results
23rd Jul 20157:00 amRNSTrading Statement
8th Jul 20155:24 pmRNSDirector/PDMR Shareholding
1st Jul 20157:00 amRNSTotal Voting Rights
8th Jun 20153:00 pmRNSDirector/PDMR Shareholding
1st Jun 20157:00 amRNSTotal Voting Rights
27th May 20152:18 pmRNSResult of AGM
22nd May 20157:00 amRNSPAYMENT OF DEFERRED CONSIDERATION
13th May 20152:17 pmRNSBlocklisting Application
6th May 20153:35 pmRNSDirector/PDMR Shareholding
29th Apr 201510:40 amRNSExercise of Options
21st Apr 201511:15 amRNSExercise of Options
16th Apr 20151:46 pmRNSIssue of Equity
9th Apr 20154:22 pmRNSDirector/PDMR Shareholding
8th Apr 20155:02 pmRNSDirector/PDMR Shareholding
31st Mar 20155:49 pmRNSDirector/PDMR Shareholding
31st Mar 20157:00 amRNSDirector/PDMR Shareholding
27th Mar 20157:00 amRNSFinal Results
11th Mar 20157:00 amRNSDirector/PDMR Shareholding
9th Mar 201512:10 pmRNSNotice of Results
3rd Mar 20157:00 amRNSAppointment of Director and Board transition
10th Feb 20154:26 pmRNSExercise of Options
9th Feb 20155:06 pmRNSDirector/PDMR Shareholding
4th Feb 20155:56 pmRNSHolding(s) in Company
4th Feb 201511:26 amRNSHolding(s) in Company
23rd Jan 201511:45 amRNSDirector/PDMR Shareholding and Exercise of Options
22nd Jan 20154:26 pmRNSDirector/PDMR Shareholding
22nd Jan 20157:00 amRNSAcquisition
20th Jan 20157:00 amRNSTrading Statement
7th Jan 201511:29 amRNSDirector/PDMR Shareholding
23rd Dec 20142:10 pmRNSNew Term Loan and Acquisition Facility
11th Nov 20143:31 pmRNSDirector/PDMR Shareholding
16th Oct 20149:42 amRNSReplacement: Director/PDMR Shareholding
8th Oct 20142:31 pmRNSDirector/PDMR Shareholding
2nd Oct 20141:53 pmRNSIssue of Equity
29th Sep 20142:49 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.